Norgine has welcomed the
PBS listing of Xifaxan (rifaximin)
550 for the treatment of hepatic
encephalopathy, which is a
deterioration of brain function that
happens when the liver is no longer
able to remove toxic substances
from the blood.
Twice daily Xifaxan treatment
plus lactulose treatment has been
shown to reduce the risk of a
breakthrough HE episode by 58%.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Dec 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Dec 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.